Simvastatin

Generic Name: Simvastatin

Brand Names: Cholib, FloLipid, Simcor, Vytorin, Zocor

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₈O_₅

CAS Number: 79902-63-9

Unique Ingredient Identifier: AGG2FN16EV

Background: Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of Aspergillus terreus. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liv...

Indication: Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).
...

Associated Conditions: Cardiovascular Events, Diabetes Mellitus, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Mixed Hyperlipidemia, History of coronary heart disease cardiovascular event, History of stroke or other cerebrovascular disease cardiovascular event

Associated Therapies: -

Clinical Trials

The DDI Study of SP2086 and Simvastatin

Phase 1

Conditions: Type 2 Diabetes

Interventions: Drug: SP2086
Drug: Simvastatin

First Posted Date: 2016-06-29

Last Posted Date: 2016-06-29

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT02817243

Locations: 🇨🇳
the First Hosital of Jilin University, Changchun, Jilin, China

The Drug-drug Interaction of SP2086 and Simvastatin

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: SP2086
Drug: Simvastatin

First Posted Date: 2016-06-28

Last Posted Date: 2016-06-28

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT02815722

Locations: 🇨🇳
People's Liberation Army General Hospital of Chengdu Military Region, Chengdu, China

Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson Disease

Interventions: Drug: Matched Placebo (for Simvastatin)
Drug: Simvastatin

First Posted Date: 2016-06-01

Last Posted Date: 2021-10-18

Lead Sponsor: University Hospital Plymouth NHS Trust

Target Recruit Count: 235

Registration Number: NCT02787590

Locations: 🇬🇧
Royal Bournemouth Hospital, Bournemouth, United Kingdom
🇬🇧
Royal United Hospital, Bath, United Kingdom
🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom

and more 21 locations

Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis

Phase 2

Completed

Conditions: Acute Pancreatitis

Interventions: Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Placebo Administration
Other: Questionnaire Administration
Drug: Simvastatin

First Posted Date: 2016-04-19

Last Posted Date: 2022-12-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT02743364

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 2 locations

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3

Recruiting

Conditions: Community-acquired Pneumonia, Influenza, COVID-19

Interventions: Other: No systemic corticosteroid
Other: No antiviral agent for COVID-19
Other: No immune modulation for COVID-19
Drug: Standard course macrolide
Other: No antiviral agent for influenza
Drug: Local standard venous thromboprophylaxis
Other: No immunoglobulin
Other: No simvastatin
Other: No cysteamine
Other: No Immune Modulator for Influenza
Other: No vitamin C
Other: No antiplatelet
Procedure: Clinician-preferred mechanical ventilation strategy
Other: No renin-angiotensin system inhibitor
Other: No endothelial modulator
Drug: Ceftriaxone
Drug: Moxifloxacin or Levofloxacin
Drug: Extended course macrolide
Drug: Fixed-duration Hydrocortisone
Drug: Five-days oseltamivir
Drug: Lopinavir / Ritonavir
Biological: Convalescent plasma
Drug: Angiotensin converting enzyme inhibitor
Drug: Nirmatrelvir/ritonavir
Drug: Therapeutic dose anticoagulation
Procedure: Protocolised mechanical ventilation strategy
Drug: Interferon beta-1a
Drug: Vitamin C
Drug: Simvastatin
Drug: Aspirin
Drug: Eritoran
Drug: Cysteamine
Drug: Imatinib
Drug: Shock-dependent hydrocortisone
Drug: Ten-days oseltamivir
Drug: P2Y12 inhibitor
Drug: Angiotensin Receptor Blockers
Drug: Conventional low dose thromboprophylaxis
Biological: Delayed administration of convalescent plasma
Drug: Piperacillin-tazobactam
Drug: Hydroxychloroquine
Drug: Anakinra
Drug: Apremilast
Drug: Baricitinib
Drug: Remdesivir
Drug: Fixed-duration higher dose Hydrocortisone
Drug: Hydroxychloroquine + lopinavir/ritonavir
Drug: Intermediate dose thromboprophylaxis
Drug: Nirmatrelvir/ritonavir + remdesivir
Drug: ARB + DMX-200
Drug: Ceftaroline
Drug: Baloxavir Marboxil
Drug: Tocilizumab
Drug: Amoxicillin-clavulanate
Drug: Fixed-duration dexamethasone
Drug: Five-days oseltamivir + baloxavir marboxil
Drug: Continuation of therapeutic dose anticoagulation
Drug: Ivermectin
Drug: Sarilumab
Drug: Ten-days oseltamivir + baloxavir marboxil

First Posted Date: 2016-04-13

Last Posted Date: 2024-07-12

Lead Sponsor: UMC Utrecht

Target Recruit Count: 20000

Registration Number: NCT02735707

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸
University of Illinois Health, Chicago, Illinois, United States
🇦🇺
Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

and more 405 locations

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Placebo for alirocumab
Drug: Alirocumab
Drug: placebo for ezetimibe
Drug: ezetimibe
Drug: atorvastatin
Drug: rosuvastatin
Drug: simvastatin

First Posted Date: 2016-03-22

Last Posted Date: 2019-09-30

Lead Sponsor: Sanofi

Target Recruit Count: 615

Registration Number: NCT02715726

Locations: 🇨🇳
Investigational Site Number 1560018, Beijing, China
🇨🇳
Investigational Site Number 1560008, Hangzhou, China
🇨🇳
Investigational Site Number 1560009, Shenyang, China

and more 59 locations

Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome

Phase 3

Completed

Conditions: Noonan Syndrome

Interventions: Drug: Placebo
Drug: Simvastatin

First Posted Date: 2016-03-21

Last Posted Date: 2023-05-11

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 53

Registration Number: NCT02713945

Locations: 🇫🇷
CHU Angers Unité d'endocrinologie pédiatrique, Angers, France
🇫🇷
Hôpital Robert Debré Unité de Génétique pédiatrique, Paris, France
🇫🇷
Chu Dijon, Dijon, France

and more 9 locations

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

Phase 1

Completed

Conditions: Dyslipidemias

Interventions: Drug: LY3202328
Drug: Placebo
Drug: Atorvastatin
Drug: Simvastatin

First Posted Date: 2016-03-21

Last Posted Date: 2021-05-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT02714569

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: Caffeine
Drug: Rosuvastatin
Drug: Atorvastatin
Drug: Simvastatin

First Posted Date: 2016-02-18

Last Posted Date: 2017-11-24

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 36

Registration Number: NCT02685462

A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MT-8554
Drug: rosuvastatin
Drug: simvastatin

First Posted Date: 2016-02-05

Last Posted Date: 2016-03-24

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 28

Registration Number: NCT02675309

Locations: 🇬🇧
Investigational center, City name, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy